Article Figures & Tables
Figures
- Fig. 1.
Effect of 100 μg/kg LPS on food intake, body weight and core body temperature in control and DIO mice. (A–C) LPS or vehicle (5 ml/kg saline) was injected i.p. 2 hours after lights on, and food intake (A; kcal % of control) and change in body weight [B,C; change (Δ)] were measured at 8 hours, and at 1, 2, 3 and 4 days after injections. (D–F) Changes in body temperature were monitored continuously by remote radiotelemetry and data are shown for 0–8 hours. (D,E) Mean change in core body temperature in control (D) and DIO (E) mice. (F) Analysis of the change in core body temperature over 0–8 hours after injection is illustrated as the area under the curve (AUC; °C.h). Data are mean ± s.e.m. for n=8–10 mice per group. *P<0.05, **P<0.01, ***P<0.001 vs respective vehicle-treated animals; $P<0.05 vs LPS-treated control animals.
- Fig. 2.
Effect of 100 μg/kg LPS on food intake, body weight and core body temperature in control and ob/ob mice. (A–C) LPS or vehicle (5 ml/kg saline) was injected i.p. 2 hours after lights on, and food intake (A; kcal % of control) and change in body weight [B,C; change (Δ)] were measured at 8 hours, and at 1, 2, 3 and 4 days after injection. (D–F) Changes in body temperature were monitored continuously by remote radiotelemetry and data are shown for 0–8 h. (D,E) Mean change in core body temperature in control (D) and ob/ob (E) mice. (F) Analysis of the change in core body temperature over 0–8 hours after injection is illustrated as the area under the curve (AUC; °C.h). Data are mean ± s.e.m. for n=6 mice per group. *P<0.05, **P<0.01, ***P<0.001 vs respective vehicle-treated animals; $P<0.05 vs LPS-treated control animals.
- Fig. 3.
Effect of 5 μg LPS on food intake, body weight and core body temperature in control and DIO mice. (A–C) LPS or vehicle (5 ml/kg saline) was injected i.p. 2 hours after lights on, and food intake (A; kcal % of control) and change in body weight [B,C; change (Δ)] were measured at 8 hours, and at 1, 2, 3 and 4 days after injection. (D–F) Changes in body temperature were monitored continuously by remote radiotelemetry and data are shown for 0–8 hours. (D,E) Mean change in core body temperature in control (D) and DIO (E) mice. (F) Analysis of the change in core body temperature over 0–8 hours after injection is illustrated as the area under the curve (AUC; °C.h). Data are mean ± s.e.m. for n=5 mice per group. *P<0.05, **P<0.01 vs respective vehicle-treated animals.
- Fig. 4.
Effect of 5 μg LPS on food intake, body weight and core body temperature in control and ob/ob mice. (A–C) LPS or vehicle (5 ml/kg saline) was injected i.p. 2 hours after lights on, and food intake (A; kcal % of control) and change in body weight [B,C; change (Δ)] were measured at 8 hours, and at 1, 2, 3 and 4 days after injection. (D–F) Changes in body temperature were monitored continuously by remote radiotelemetry and data are shown for 0–8 hours. (D,E) Mean change in core body temperature in control (D) and ob/ob (E) mice. (F) Analysis of the change in core body temperature over 0–8 hours after injection is illustrated as the area under the curve (AUC; °C.h). Data are mean ± s.e.m. for n=6 mice per group. *P<0.05, **P<0.01, ***P<0.001 vs respective vehicle-treated animals; $P<0.05 vs LPS-treated control animals.
- Fig. 5.
Effect of i.p. injection of LPS on Fos protein expression in the brains of control, DIO and ob/ob mice. (A) Representative photomicrographs illustrating Fos expression in the brain of control (a–d and i–l) or DIO (e–h and m–p) mice after i.p. injection of vehicle (5 ml saline/kg body weight) or LPS (100 μg/kg body weight). After LPS injection, significant increases in Fos expression were observed in the SFO (a,b,e,f) and SON (c,d,g,h) in control mice only, and in the PVN (i,j,m,n), NTS (k,l,o,p) and AP (k,l,o,p) of control and DIO mice, although the number of Fos-positive cells in response to LPS was lower in DIO compared with control mice. Scale bars: 100 μm. 3V, third ventricle; cc, central canal. (B) Quantification of the number of Fos-positive nuclei per section in DIO mice. (C) Quantification of the number of Fos-positive nuclei per section in ob/ob mice. No photomicrographs are shown for ob/ob mice because findings were similar to DIO mice. Data are mean ± s.e.m. for n=5 mice per group. *P<0.05, **P<0.01, ***P<0.001 vs respective vehicle-treated group; #P<0.05, ##P<0.01 versus LPS-treated control; $P<0.05, $$P<0.01 versus vehicle-treated control.
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Other journals from The Company of Biologists
DMM and COVID-19
We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.
Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.
The twin pillars of Disease Models & Mechanisms
In her first Editorial as Editor-in-Chief, Liz Patton sets out her vision and priorities for DMM focusing on four thematic challenges: mechanisms of disease, innovative technologies, disease progression through time and therapy.
Extended deadline - The RAS Pathway: Diseases, Therapeutics and Beyond
Our upcoming special issue is welcoming submissions until 3 May 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on the targeting the RAS pathway.
Find out more about the issue and how to submit your manuscript.
Perspective - Modelling the developmental origins of paediatric cancer to improve patient outcomes
James Amatruda authors our first Perspective, discussing some of the key challenges in paediatric cancer from his perspective as a physician-scientist.
A muscle growth-promoting treatment based on the attenuation of activin/myostatin signalling results in long-term testicular abnormalities
In this issue’s Editor’s choice, Ketan Patel and colleagues describe how even brief exposure to muscle-growth-promoting treatments exerts a long-term detrimental effect on the testes, and test promising therapeutics to mitigate this side-effect.